Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.76 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.97M

Average 1.17M

RCUS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Arcus Biosciences, Inc.NYSE: RCUS

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $7M.

Context

  • Cost of revenue amounted to 4.0% of revenue in FY2025, up 4.0 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.75M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$10M— YoY
LTMJun 2026
$7M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
10M USD
Year-over-year change
—

Cost of Revenue vs competitors

How RCUS compares with its peers on the latest reported figures

  • RCUS's LTM Jun 2026 cost of revenue of $7M is the 3rd highest of the 9 companies compared; the peer median is $5.94M.
  • Cost of revenue amounts to 6.0% of revenue for RCUS, versus a peer median of 7.5%.
RCUS Competitors Peer median
Cost of Revenue for RCUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$33.93M +492.3%+66.7%7.5%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$11.84M +58.0%+89.1%17.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$7M ——6.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$6.64M +19.4%+13.1%12.8%
IBRXImmunityBio, Inc.LTM Sep 2026$6.07M +40.5%—3.3%
DNLIDenali Therapeutics Inc.LTM Jun 2026$5.8M ——161.0%
COGTCogent Biosciences, Inc.LTM Jun 2026$2.33M +101.6%——
VRDNViridian Therapeutics, Inc.LTM Jun 2026$320K ——0.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 —-58.5%0.0%
Peer median (excluding RCUS) $5.94M+58.0%+39.9%7.5%

Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue383M112M117M258M247M
Cost of Revenue000010M
Gross Profit383M112M117M258M237M
Gross Margin100.0%100.0%100.0%100.0%96.0%
Research & Development257M288M340M448M523M
Selling, General & Admin72M104M117M120M110M
Operating Expenses329M392M457M588M623M
Depreciation & Amortization4M6M8M10M10M
EBITDA59M(258M)(291M)(269M)(335M)
EBITDA Margin15.4%-230.4%-248.7%-104.3%-135.6%
Operating Income54M(280M)(340M)(330M)(386M)
Operating Margin14.1%-250.0%-290.6%-127.9%-156.3%
Interest Income1M16M41M52M41M
Interest Expense02M2M4M8M
Other Income / Expenses1M14M39M47M33M
Income Before Tax55M(266M)(301M)(283M)(353M)
Pre-Tax Margin14.4%-237.5%-257.3%-109.7%-142.9%
Income Tax Expense2M1M6M1M0
Net Income53M(267M)(307M)(283M)(353M)
Net Margin13.8%-238.4%-262.4%-109.7%-142.9%
EPS (Basic)0.76(3.71)(4.15)(3.14)(3.29)
EPS (Diluted)0.71(3.71)(4.15)(3.14)(3.29)
Weighted Avg Shares69.35M72M74M90.1M107.4M
Weighted Avg Shares (Diluted)73.97M72M74M90.1M107.4M

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.